 HIV Antibodies
"HIV Antibodies" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antibodies reactive with HIV ANTIGENS.
| Descriptor ID |
D015483
|
| MeSH Number(s) |
D12.776.124.486.485.114.254.150.440 D12.776.124.790.651.114.254.150.440 D12.776.377.715.548.114.254.150.440
|
| Concept/Terms |
HIV Antibodies- HIV Antibodies
- Antibodies, HIV
- HIV Associated Antibodies
- Antibodies, HIV Associated
- HIV-Associated Antibodies
- Antibodies, HIV-Associated
- HTLV III Antibodies
- Antibodies, HTLV III
- HTLV III LAV Antibodies
- T-Lymphotropic Virus Type III Antibodies, Human
- HTLV-III-LAV Antibodies
- Antibodies, HTLV-III-LAV
- LAV Antibodies
- Antibodies, LAV
- Lymphadenopathy Associated Antibodies
- Antibodies, Lymphadenopathy Associated
- Lymphadenopathy-Associated Antibodies
- Antibodies, Lymphadenopathy-Associated
- T Lymphotropic Virus Type III Antibodies, Human
- AIDS Antibodies
- Antibodies, AIDS
- HTLV-III Antibodies
- Antibodies, HTLV-III
|
Below are MeSH descriptors whose meaning is more general than "HIV Antibodies".
Below are MeSH descriptors whose meaning is more specific than "HIV Antibodies".
This graph shows the total number of publications written about "HIV Antibodies" by people in this website by year, and whether "HIV Antibodies" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 0 | 1 | 1 | | 2000 | 1 | 0 | 1 | | 2004 | 0 | 1 | 1 | | 2005 | 0 | 1 | 1 | | 2006 | 0 | 2 | 2 | | 2007 | 1 | 0 | 1 | | 2010 | 0 | 1 | 1 | | 2011 | 0 | 1 | 1 | | 2012 | 3 | 0 | 3 | | 2013 | 1 | 0 | 1 | | 2014 | 4 | 2 | 6 | | 2015 | 0 | 2 | 2 | | 2017 | 3 | 1 | 4 | | 2018 | 1 | 2 | 3 | | 2019 | 2 | 2 | 4 | | 2020 | 2 | 0 | 2 | | 2021 | 3 | 3 | 6 | | 2022 | 1 | 3 | 4 | | 2023 | 0 | 2 | 2 | | 2024 | 1 | 1 | 2 | | 2025 | 6 | 0 | 6 | | 2026 | 1 | 1 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "HIV Antibodies" by people in Profiles.
-
Khaitan A, Lindsey JC, Capparelli EV, Tierney C, Coletti A, Perlowski C, Yin DE, Smith MEB, Spiegel HML, Majji S, Moye J, Gama L, Koup RA, Lin BC, McDermott AB, Purdue L, Krotje C, Harding PA, Cotton MF, Costello D, Petropoulos CJ, Reeves JD, Mallewa M, Chihana R, Kamthunzi P, Mbengeranwa TG, Masheto G, Santos Cruz ML, Pilotto JH, Ponatshego PL, Persaud D, McFarland EJ. VRC01 with antiretroviral initiation in infants is well tolerated, and higher concentrations associate with greater HIV-1 DNA declines. Sci Transl Med. 2026 May 06; 18(848):eadr4509.
-
Huynh D, Nikanjam M, Cunningham CK, McFarland EJ, Muresan P, Perlowski C, Yin DE, Moye J, Spiegel H, Gama L, Gaudinski M, Capparelli EV. Model-based assessment of VRC07-523LS dosing in infants through population pharmacokinetic -pharmacodynamic modelling in adults and infants. J Antimicrob Chemother. 2026 Jan 19; 81(2).
-
Parks KR, Moodie Z, Allen MA, Yen C, Furch BD, MacPhee KJ, Ozorowski G, Heptinstall J, Hahn WO, Zheng Z, Lu H, Grant S, Domin E, Duff MO, Seese A, Marini-Macouzet C, Ballweber-Fleming L, Lee WH, Cottrell CA, Liguori A, Georgeson E, Alavi N, Kubitz M, Phelps N, Seaton KE, Cohen KW, Anderson MA, Mondal K, Laufer DS, Kublin JG, Ward AB, Hyrien O, De Rosa SC, Himansu S, Leav B, Reuter C, Tomaras GD, Montefiori D, Walsh SR, Frank I, Sobieszczyk ME, Goepfert PA, Stephenson KE, Baden LR, Van Tieu H, Keefer MC, Clark J, Riddler SA, Schief WR, McElrath MJ. Vaccination with mRNA-encoded membrane-anchored HIV envelope trimers elicited tier 2 neutralizing antibodies in a phase 1 clinical trial. Sci Transl Med. 2025 Jul 30; 17(809):eady6831.
-
Filsinger Interrante MV, Tang S, Kim S, Shanker VR, Hie BL, Bruun TUJ, Wu W, Pak JE, Fernandez D, Kim PS. Utilizing Machine Learning to Improve Neutralization Potency of an HIV-1 Antibody Targeting the gp41 N-Heptad Repeat. ACS Chem Biol. 2025 Jul 18; 20(7):1470-1480.
-
Kim S, Radford CE, Xu D, Zhong J, Do J, Pham DM, Travisano KA, Filsinger Interrante MV, Bruun TUJ, Rezek V, Wilder B, Palomares M, Seaman MS, Kitchen SG, Bloom JD, Kim PS. A broad antibody with enhanced HIV-1 neutralization via bispecific antibody-mediated prepositioning. Nat Commun. 2025 May 18; 16(1):4617.
-
Feist WN, Luna SE, Ben-Efraim K, Filsinger Interrante MV, Amorin A, Johnston NM, Bruun TUJ, Utz A, Ghanim HY, Lesch BJ, McLaughlin TM, Dudek AM, Porteus MH. Multilayered HIV-1 resistance in HSPCs through CCR5 Knockout and B cell secretion of HIV-inhibiting antibodies. Nat Commun. 2025 Apr 01; 16(1):3103.
-
Alba C, Malhotra S, Horsfall S, Barnhart ME, Bekker A, Chapman K, Cunningham CK, Fast PE, Fouda GG, Freedberg KA, Goga A, Ghazaryan LR, Leroy V, Mann C, McCluskey MM, McFarland EJ, Muturi-Kioi V, Permar SR, Shapiro R, Sok D, Stranix-Chibanda L, Weinstein MC, Ciaranello AL, Dugdale CM. Cost-effectiveness of broadly neutralizing antibodies for HIV prophylaxis for infants born in settings with high HIV burdens. PLoS One. 2025; 20(3):e0318940.
-
Cunningham CK, McFarland EJ, Muresan P, Capparelli EV, Perlowski C, Johnston B, Bone F, Purdue L, Yin DE, Moye J, Spiegel HML, Majji S, Theron GB, Mujuru HA, Purswani M, Alvarez G, Deville JG, Chambers C, Brown E, Harding PA, Tobin NH, Low K, Gama L. Safety, Tolerability, and Pharmacokinetics of Long-Acting Broadly Neutralizing HIV-1 Monoclonal Antibody VRC07-523LS in Newborn Infants Exposed to HIV-1. J Pediatric Infect Dis Soc. 2025 Feb 06; 14(2).
-
Kalams SA, Felber BK, Mullins JI, Scott HM, Allen MA, De Rosa SC, Heptinstall J, Tomaras GD, Hu J, DeCamp AC, Rosati M, Bear J, Pensiero MN, Eldridge J, Egan MA, Hannaman D, McElrath MJ, Pavlakis GN. Focusing HIV-1 Gag T cell responses to highly conserved regions by DNA vaccination in HVTN 119. JCI Insight. 2024 Aug 01; 9(18).
-
Frank I, Li SS, Grunenberg N, Overton ET, Robinson ST, Zheng H, Seaton KE, Heptinstall JR, Allen MA, Mayer KH, Culver DA, Keefer MC, Edupuganti S, Pensiero MN, Mehra VL, De Rosa SC, Morris DE, Wang S, Seaman MS, Montefiori DC, Ferrari G, Tomaras GD, Kublin JG, Corey L, Lu S. Safety and immunogenicity of a polyvalent DNA-protein HIV vaccine with matched Env immunogens delivered as a prime-boost regimen or coadministered in HIV-uninfected adults in the USA (HVTN 124): a phase 1, placebo-controlled, double-blind randomised controlled trial. Lancet HIV. 2024 05; 11(5):e285-e299.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|